Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Minneapolis, Minnesota 55404


This is the first study in hemodialysis subjects with anemia to evaluate the pharmacokinetics, safety, efficacy, tolerability, and pharmacodynamics of sotatercept (ACE-011)

Study summary:

Part 1: Approximately 8 subjects will be randomized to receive either a single 0.1 mg/kg subcutaneous dose of sotatercept or matching placebo in a 3:1 ratio Part 2: Approximately 8 subjects will be randomized to each of the 3 sequential dose groups (0.3mg/kg or 0.5mg/kg or 0.7 mg/kg) with a 3:1 ratio of sotatercept or placebo (6 subjects in the sotatercept arm and 2 in the placebo arm). A total of 24-36 subjects may be randomized in the 3 dose groups.


Inclusion Criteria: - Males or females ≥18 years of age. - Subjects on hemodialysis for at least 12 weeks before screening - Subjects on a stable dose of Erythrocyte Stimulating Agents product to maintain Hemoglobin (Hb) for at least 6 weeks prior to screening. - 3 consecutive pre-dialysis Hb concentrations with a mean ≥10 to ≤ 12 g/dL (≥100 to ≤120 g/L) at screening and one pre-dialysis Hb concentration ≥8 to < 10 g/dL (≥ 80 to < 100 g/L) before randomization. - Adequate iron status defined as serum transferrin saturation ≥ 20% before randomization. Exclusion Criteria: - Non renal causes of anemia. - Subjects on peritoneal dialysis. - Systemic hematological disease - High sensitivity C-reactive protein >50mg/L at screening. - Alanine transaminase (ALT) or aspartate transaminase (AST) laboratory values > 2 times the upper limit of normal (ULN) at screening. - Uncontrolled diabetes mellitus (HbA1c > 9) at screening. - Uncontrolled hypertension. - Red Blood Count (RBC) transfusions within 8 weeks prior to screening. - Active serious infection or history of recurrent serious infection likely to recur during the study - History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product or to the iron products needed to normalize iron levels for subjects. - Subjects that received treatment with another investigational drug or device within 28 days prior to Day 1 - Pregnant or lactating females.



Primary Contact:

Study Director
William T Smith, MD
Celgene Corporation

Backup Contact:


Location Contact:

Minneapolis, Minnesota 55404
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.